Spreading ideas to enable radical life extension and a sci-fi future @FreeRadicalsBio. Strategy principal @ Google, prev. McKinsey and Neuro / Physics @ Penn
Some of the proteins in your body last for decades, accumulating chemical damage your body can’t remove. While most of the aging field is working on cellular rejuvenation, Aaron Cravens (@crav1ngcravens) is building enzymes to clean up that damage.
His company, Revel Pharmaceuticals (@revelpharma), engineered an enzyme that removed decades’ worth of one form of damage from donated human tissue in the lab. The results attracted attention from the New York Times and Bryan Johnson (@bryan_johnson).
Eric Dai (@EricDai_BioE) and I sat down with Aaron on Free Radicals (@FreeRadicalsBio) to discuss the science behind the headlines, how AI helped make it possible, what it will take to turn this into a treatment, and how to build the SpaceX of longevity.
Full episode in my reply, or look up Free Radicals on your favorite podcasting platform.
Free Radicals is back! Apologies for the brief pause - Eric and I have each been working on exciting projects in the longevity space that we’ll share more on soon.
Introducing Helios: measuring 1,000+ protein biomarkers from a drop of blood to help you live younger, longer.
Here’s how it works:
• Self-collect blood at home with a painless, needle-free device
• We measure the proteins carrying signals from cells and organs throughout your body
• Your Helios AI agent explains your results, highlights risks, and offers personalized guidance
Proudly backed by Y Combinator and Formation VC.
Join the waitlist at https://t.co/ZFcLlzMFK2
00:00 The enzyme that went viral
03:45 Why target the body’s “rust”?
06:41 Repairing damage vs. reprogramming
14:31 Building a repair shop for aging
19:40 Enzymes: biology’s cleanup crew
24:08 Getting enzymes into patients
30:28 AI, skepticism, and longevity’s promise
36:55 Building the SpaceX of longevity
44:51 What longevity’s breakthrough looks like
51:40 Rejuvenation you can actually feel
54:51 Will longevity be only for billionaires?
58:54 Where we’d place our longevity bets
1:04:12 Why Aaron chose aging over finance
Some of the proteins in your body last for decades, accumulating chemical damage your body can’t remove. While most of the aging field is working on cellular rejuvenation, Aaron Cravens (@crav1ngcravens) is building enzymes to clean up that damage.
His company, Revel Pharmaceuticals (@revelpharma), engineered an enzyme that removed decades’ worth of one form of damage from donated human tissue in the lab. The results attracted attention from the New York Times and Bryan Johnson (@bryan_johnson).
Eric Dai (@EricDai_BioE) and I sat down with Aaron on Free Radicals (@FreeRadicalsBio) to discuss the science behind the headlines, how AI helped make it possible, what it will take to turn this into a treatment, and how to build the SpaceX of longevity.
Full episode in my reply, or look up Free Radicals on your favorite podcasting platform.
Free Radicals is back! Apologies for the brief pause - Eric and I have each been working on exciting projects in the longevity space that we’ll share more on soon.
In partnership with Vinod Khosla (@vkhosla), I’m proud to introduce Reservoir.
Billionaires have owned their cells for years. Starting today, you can too.
Sign up today: https://t.co/JftHvfPx6A
We've built the worlds most accessible brain-computer interface.
A device built for clean signal, a personal model that learns your brain, and an AI platform to build with it.
This is Kyma.
Preorders for our founding batch are now open.
The McGuires are incredible founders and I am so inspired that they've chosen to tackle one of the most important technologies for the future of human health. Proud to be an investor.
If you're an engineer, surgeon or operator looking to contribute to the mission, reach out!
https://t.co/D2YoS9wtrq
@dylanmcguir3 and I just raised a $7.5M pre-seed led by @a16z to build a robotic surgeon @alephsurgery
Much of the early investment in Physical AI has focused on industries where labor is relatively abundant and low-cost. We believe the biggest opportunities to change the world lie at the opposite end of the spectrum.
Surgery is among the most valuable forms of labor on the planet, but it's far too scarce and expensive - due to an exceptionally long training pipeline and highly concentrated expertise.
We’re building the first surgeon that scales: one system that can acquire, refine, and transfer surgical skills across millions of procedures. v1 is already learning to perform surgical tasks autonomously from demonstrations, and improve from its own experience.
Lots of great folks behind us! @BoxGroup, Reveille VC, Constellation, @forward_deploy, @Valkyrie_vc, @DiscipulusVent, @maniacvc + more
@dylanmcguir3 and I just raised a $7.5M pre-seed led by @a16z to build a robotic surgeon @alephsurgery
Much of the early investment in Physical AI has focused on industries where labor is relatively abundant and low-cost. We believe the biggest opportunities to change the world lie at the opposite end of the spectrum.
Surgery is among the most valuable forms of labor on the planet, but it's far too scarce and expensive - due to an exceptionally long training pipeline and highly concentrated expertise.
We’re building the first surgeon that scales: one system that can acquire, refine, and transfer surgical skills across millions of procedures. v1 is already learning to perform surgical tasks autonomously from demonstrations, and improve from its own experience.
Lots of great folks behind us! @BoxGroup, Reveille VC, Constellation, @forward_deploy, @Valkyrie_vc, @DiscipulusVent, @maniacvc + more
Here's a glimpse behind the curtain at Neion Bio.
In biotech, we often take manufacturing for granted but it is fundamental to innovation. "Those serious about software should make their own hardware." The same is true in biology.
The manufacturing of life-saving biopharma medicines has been stagnant for decades. Legacy technologies that rely on a single type of cell reached diminishing returns in the late 2000s. In order to squeeze out more we relocated these factories in areas with lower costs ex-US.
Spending billions to rebuild this infrastructure domestically using largely the same legacy technologies is fighting a losing battle. Sure there may be an incremental improvement here and there but these facilities will be uncompetitive as soon as they go live (if they ever go live).
We now have the ability to efficiently and accurately reprogram complex biological systems, so why are we restricting ourselves to the small sliver of biology that happened to work 50 years ago?
Thanks @teleodaniel and @EricDai_BioE for helping tell our story.
Producing the 3 to 5 grams of a biologic needed for IND-enabling studies costs millions of dollars using traditional CHO manufacturing.
A single egg, meanwhile, contains 6 grams of protein, costs just 10 cents, and requires only chicken feed and water as inputs.
Neion Bio is taking advantage of this incredible technology to turn chickens into drug factories. And they’ve already signed a commercial deal with a drugmaker to produce biosimilars.
With AI leaders promising to unleash countless new therapies, we’re going to need to scale up our manufacturing. That sci-fi future may be one where we stop producing drugs in huge steel tanks, and instead start farming them like we do our food.
We sat down with co-founders Dimi Kellari and Sam Levin to discuss this future. [Disclosure: I’m an investor, though I wasn’t at the time of recording.]
Watch the full episode below, or look up Free Radicals (@FreeRadicalsBio) on your favorite podcasting platform.
Thank you to @SynBioBeta for hosting us!
0:00 Intro
1:07 What Neion Bio does
4:53 How the founders arrived at synthetic biology and chickens
10:21 Biosimilars as Neion’s first commercial market
13:30 Why farming drugs is a viable path to reshoring biomanufacturing
18:38 Neion’s technical moat & why engineering birds is difficult
25:50 Advantages of chicken-based manufacturing
30:06 Why CHO manufacturing became the industry standard
33:21 What it takes to disrupt CHO manufacturing
37:57 What it means to program biology
42:48 Skepticism around this new manufacturing approach
47:00 Applying tech principles to biotech
55:34 Natural intelligence vs artificial intelligence
57:14 The future of farming drugs & programmable chickens
More than 20 years ago, I coined the term Biosingularity to define a time when we can engineer new biological systems and have complete molecular control over existing life forms, including reversing aging and upgrading to Human 2.0. My timeline for this is latest early 2040 now.
Let's make a concrete plan to 'cure every disease in 10y' and see how far we could get.
Our assumptions will be ~infinite IQ 200+ 'thinkers', automated labs by ~2032, $1-2T to spend (~10y Google profits), can recruit any living person, significant influence over US Gov but not omnipotence.
There are three problems to solve:
1) Knowing how to cure a disease.
2) Making the medicine to do it.
3) Showing that you've done it (in humans).
Difficulty on this timeline is 3>1>>2. We will need to identify longest critical path timelines for each problem, and do things in parallel.
We'll use siRNA for loss of function and LNP mRNA for gain of function, because this gives access to every target in the genome and makes transition from knowing through drug design very fast (if you assume AI has enough training data zero shot a small molecule for any target, could use that as well).
We will need manufacturing capacity, which can be built while we sort out what to do, COVID-style. Number of disease x person cases to treat in US is ~1B, which would mean ~1000x current capacity, at cost of ~$100B and requiring ~5M workers. Let's assume the workers can be robots by our deadline date. Let's assume AI makes the molecules 20x more potent/gram, then this expansion could cover global demand.
Main limitation of these drug modalities is not reaching all cell types. To solve this we will have AI nominate conjugated ligands for all cell types based on existing scSeq + proteomic Atlases, create libraries of these and use pooled in vivo screening of a whole organism to thoroughly map biodistribution for each. We'll prototype in primates to get methodology down, then will confirm using 3-5 human decedents (has been done for AAV serotype screens). 5-100B dollars depending on how deep you go on cell count. These conjugates will ~modularly map to any oligo sequence we come up with later. From experience this could be done in <3y.
Showing effects in humans will be the slowest part, particularly for progressive and hard-to-measure disease like Alzheimer's. To make our timeline we will have to develop at minimum prognostic and pharmacodynamic biomarkers for every disease where readouts take >2y. Let's assume doing multiple -omics on blood contains patterns that AI can infer as disease activity.
You might pair this with video records of people with/without disease (either as new study in parallel, or get CCTV from China maybe), assuming AI can track behavioral & functional capacity as added data.
We want access to samples with causal information on disease, ideally timecourse with incidence of lots of diseases. The US Veteran's Admin has blood samples over many years from many many veterans. We'll spend year 1 working with USG to produce multi-omic data to pair with these health records, as has been done at mid scale with UK Biobank. By year 3 this could give us potential prognostic markers for all diseases. We'll come back to these.
For question 1, any sound thinker will tell you that some interventions will treat some cells while messing up others. So we will need two sets of data: First, understand every treatment's effect in every cell. We (today, only @GordianBio) can do this with pooled in vivo screening, in animals that have already developed the diseases to avoid waiting, to understand what does good/bad things in each cell type.
In parallel, we will start testing safety of the treatments in healthy human volunteers, doing dose escalation of ~40 people x 20k x up/down at 50K per patient (just blood draws) would be like 80B dollars, and within order of mag of how many patients are recruited for (all) trials today (if you think this is daunting, spend 1y doing in mice first). From this we will 1) get toxicity for each target, 2) draw blood and get pharmacodynamic markers for each target, 3) measure blood changes for AI to compare to the VA data, as well as to the cellular changes from the pooled screen, to deconstruct the physiological changes from cellular effects.
So year 4ish you have treatments in animals that benefit each disease/cell type, you put together the data on which interventions cause which types of toxicity systemically with what effects occur in each cell types to learn what cell types to avoid for each target, and use biodistribution data to design around that.
This tells you what interventions where, so you use and/or combine those into trials in diseased patients (~600B for 25K diseases, 4 treatments per), initially with multiple treatment arms for each of your hypotheses and biomarker readouts based on the blood omics for efficacy potential. Get more blood, calibrate, pick best options. Say 3 rounds of 1y trials. All paperwork and analysis ~instant because AI.
We'll try combinations too based on the causal in vivo map, using AI to identify synergies based on effects and inferring regulatory/interactome networks and cell-cell interactions.
If you're good at this you now have a strong treatment for each disease, could imagine running a pivotal with just one or two hundred patients, say 20M and 2y, 500B if 25K diseases (in reality less because most of those 25K diseases are rare+genetic).
Key thing is that the manufacturing scaleup, the delivery enablement, the target discovery, and the biomarker development happen in parallel in the first ~3-4 years, leaving time for a few rounds of biomarker-based trials and then one pivotal per disease.
We'll fall short of 'all diseases', missing: Ones not present in VA data, ones with no natural model system (although we should try ex vivo human organs), a few where neither KD or overexpression solves.
FDA approval may have to wait a few more years to wait for pivotal trial hard endpoints if biomarkers not considered validated surrogates yet.
And of course everything has to go right, etc. etc.
But there's at least directions we can start today that make amazing outcomes happen in our lifetimes.
(h/t discussions with @SGRodriques)
Twenty years ago, @DeryaTR_ predicted we would reverse aging by 2045. People thought he was crazy.
Now, he thinks he was too conservative, and has moved the date up to 2040 because AGI arrived earlier than he expected.
I sat down with Derya to ask if such bold predictions are too fatalistic. Is the future guaranteed? Shall we just sit back and wait for AI to save us? Derya disagreed.
The golden age for humanity is within our sights, but there is much work to be done.
Academia is failing us. If it doesn’t adapt to the pace of progress AI enables, we have no shot at curing aging this century. And we need to invest trillions into collecting the data that superintelligence will need to solve biology.
If we pull it off, the future can be brighter than anyone imagines.
Watch the full episode below, or look up Free Radicals (@FreeRadicalsBio) on your favorite podcasting platform.
Special thank you to @adamgries and https://t.co/QjCQKgN4Zj for hosting us at @VitalistBay!
Intro
AGI arrived early, accelerating the timeline to biosingularity
Are we really in the takeoff now?
Superintelligence can help us build a world model of biology
Aging as the breakdown of biological resilience
The case for investing trillions into biological data
The economic return on curing aging
AI is accelerating science but academics are stuck in the past
How AI can liberate humanity from biological constraints
Derya’s Human 2.0 dream
Testing the latest OpenAI models and rethinking the PhD
Agency, jobs, and free will in an AI world
Science fiction & Derya’s case for a coming golden age